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The Role of Releasing Hormones in the
Diagnosis of Hypopituitarism
AN ANALYSIS OF 9 PATIENTS
L. A. DISTILLER, J. E. MORLEY, S. ZAIL
SUMMARY
Luteinising hormone-releasing factor and thyrotrophin-
releasing factor were used in conjunction with the insulin
tolerance test in 9 patients with known or suspected
panhypopituitarism. It appears that growth hormone and
luteinising hormone fail early in panhypopituitarism. Cor-
tisol and thyroid-stimulating hormone production fail later.
On the basis of this study, it is suggested that luteinising
hormone-releasing factor, alone or combined with thyro-
trophin-releasing factor, may prove a suitable sensitive
screening test of pituitary function in patients with pan-
hypopituitarism due to pituitary tumour or occurring after
radiation therapy. The hypothalamic type of response seen
after administration of the two releasing factors in many
of the patients in this series who had had radiation therapy
to the pituitary gland, suggests that hypothala'mic damage
may follow this form of therapy.
S. Afr. Med. J., 48, 1612 (1974).
During the past decade the recognition, isolation and syn-
thesis of hypothalamic releasing factors has opened new
horizons in the understanding of hypothalamic-pituitary
interactions. More particularly, the availability of luteinis-
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ing hormone-releasing factor (LHRF) and thyrotrophin-
releasing factor (TRF) has widened the diagnostic ap-
proach to the investigation of hypopituitarism.
It is widely quoted in standard texts' and reviews' of the
pituitary gland that there is a progressive selective loss of
anterior pituitary function in lesions of the pituitary gland
in the following order: (i) gonadotrophins, (ii) growth hor-
mone, (Ui) ACfH or TSH. This observation is based on
extensive clinical experience. Combined testing of reserves
of human growth hormone (HGH), cortisol, luteinising
hormone (LH) and thyroid-stimulating hormone (TSH)
in various degrees of hypopituitarism should confirm this
concept.
Until recently the primary diagnostic procedure utilised
in the assessment of panhypopituitarism was the HGH and
cortisol response to insulin-induced hypoglycaemia: An
alternative, less stressful means of screening patients with
pituitary disease may prove useful. Both LHRF and TRF
administration are harmless and virtually free of all side-
effects:"
In order to investigate these possibilities we have ana-
lysed 'total' pituitary function in 9 patients presenting
with hypopituitarism.
PATIENTS AND METHODS
Nine patients with known or suspected panhypopituitarism
were admitted to the study. The clinical features are listed
in Table I. Seven of the 9 patients had proven pituitary
tumours treated by radiation therapy with or without sur-
gery, and these 7 patients were already on long-term
thyroid and corticosteroid replacement. In these instances
TABLE I. CLINICAL DETAILS OF PATIENTS STUDIED
Patient Age Sex Presenting feature Diagnosis Treatment
1 67 F Headache Pituitary tumour Radiation therapy
2 47 M Visual disturbance Pituitary tumour Surgery and radiation therapy
3 33 M Headache and weakness Pituitary tumour Surgery and radiation therapy
4 47 F Headache Pituitary tumour Radiation therapy
5 50 F Visual disturbance Pituitary tumour Surgery and radiation therapy
6 23 F Amenorrhoea Idiopathic hypopituitarism Nil
7 34 M Headache and visual Pituitary tumour Surgery and radiation therapy
disturbance
8 38 M Weakness Sarcoidosis of pituitary Nil
9 26 F Headache Malignant chordoma of Surgery and radiation therapy
pituitary
10 Augustus 1974 S.-A. MEDIESE TYDSKRIF 1613
thyroid replacement was withheld for six weeks and the
corticosteroid replacement was withheld for one week,
under observation, prior to testing. In patient 9 it was
considered inadvisable to withhold corticosteroids and
therefore cortisol measurements could not be performed.
The following tests were performed:
Standard insulin tolerance test; using 0,1 - 0.15 units / kg
body weight soluble insulin, with measurement of serum
HGH and cortisol response basally and at 30, 60 and 120
minutes. Blood was withdrawn via an indwelling venous
catheter. In all cases adequate hypoglycaemia was attained,
i.e. the blood sugar decreased to below 40 mg/IOO m!.
LHRF was given as a 200-fLg intravenous bolus, and
blood was withdrawn for serum LH estimations basally
and at 30, 60 and 120 minutes.
TRF was given as a 200-fLg intravenous bolus, and
blood was withdrawn for serum TSH estimations basally
and at 20, 40 and 60 minutes·
Serum HGH, LH and TSH were measured by a double-
antibody radio-immunoassay technique using kits supplied
by CEA-Sorin. Serum cortisol was measured by a com-
petitive protein-binding assay.'
In the first 5 patients, the three tests were performed on
three consecutive days, _but following the demonstration
that these tests may be combined without interference with
the various responses,"- the remaining 4 patients were
investigated by combining the three tests over a single two-
hour period.
RESULTS
The results obtained are graphically illustrated in Fig. 1.
A wide variation in response was obtained. With the ex-
ception of patient 5, who had no biochemical evidence of
hypopituitarism despite pituitary surgery and radiation
therapy 12 years previously, the patients showed
variou3 degrees of pituitary hypofunction. In all but 1
patient. HGH and LH function were similarly impaired,
but in patient S there was HGH loss with some LH
reserve still present. In all 8 patients with pituitary dys-
fU:1ction, HGH and LH failed before cortisol and TSH.
In 4 of the patients who had had radiation therapy to
the: pituitary gland, the pattern of the TSH response was
abnormal in that there was a delay in the peak response
and a delayed return to basal levels. This type of response
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Fig. 1. Pituitary responses to stimulation tests (T,-lodine measured in jlg/IOO mI).
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DISCUSSION
This series demonstrates that HGH is probably the first
hormone to fail in hypopituitarism. It appears to be closely
related to failure of LH secretion, but preceded it in I of
our patients. As anticipated on clinical grounds, TSH and
ACTH loss occurred later.
The TSH response to TRF has been shown to be an
extremely sensitive test of thyroid function,'· but never-
theless it is interesting to note that the serum T.-iodine may
remain well within normal limits, in spite of obviously
failing TSH secretion. This would suggest that routine
serum biochemistry is a very poor measure of thyroid re-
serve in patients with hypopituitarism, a finding which has
also been documented by Hajjer et at. ID
The insulin tolerance test is contra-indicated in patients
with ischaemic heart disease. It is difficult to perform in
the presence of diabetes mellitus and the HGH response
may be impaired in patients with obesity," psychological
growth retardation," and delayed puberty.l3 The test is un-
pleasant and not without hazard. Furthermore, in patients
who have been on prolonged corticosteroid replacement,
the duration and degree of pituitary corticotrophin sup-
pression is unpredictable, and this may make interpretation
of a poor cortisol response to the insulin tolerance test
difficult.
For all these reasons an alternative, harmless and easily
administered sensitive screening test of pituitary function
would be useful in cases of suspected panhypopituitarism.
On the basis of the results presented it is suggested that
measurement of the LH response to LHRF may fulfil many
of the necessary requirements. Should the pituitary respond
adequately to the intravenous administration of LHRF,
this would virtually exclude early hypopituitarism due to
pituitary tumour or after radiation therapy. However, a
flat LH response to LHRF would require further exten-
sive investigation to determine the extent of pituitary
disease and to exclude hypothalamic disease, since it has
been well demonstrated that prolonged hypothalamic mal-
function may produce a pituitary gland non-responsive to
LHRF.H
At the other end of the spectrum, a TRF stimulation
test may be useful as a marker of the degree of panhypo-
pituitarism. An absent TSH response to TRF would be
suggestive of total panhypopituitarism.
It may therefore be recommended that in cases where
the insulin tolerance test is contra-indicated or difficult to
interpret, a combined LHRF/TRF test could suffice as an
alternative means of assessing the two extremes of the
pituitary hormonal production spectrum.
The hypothalamic type of hormonal response seen in
many patients who underwent radiation therapy to the
pituitary fossa may imply hypothalamic radiation damage
and tends to confirm previous reports that external radia-
tion therapy of the pituitary fossa may result in hypothala-
mic destruction.H This highlights the importance of lumbar
air encephalography in all cases of pituitary tumour, in
order to localise more accurately the extent of the neo-
plasm and thereby make radiation therapy more accurate
in an attempt to avoid damage to surrounding tissues.
We wish to thank Ayerst International (SA) for supply-
ing LHRF and Roche Products (Pty) Ltd for the TRF used
in this study.
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